Company news
Axim Biotechnologies, Inc. (OTC:AXIM) news
Axim Biotechnologies, Inc. news releases on 6ix. Latest, Dec 12, 2017: AXIM Biotech Announces Successful Completion of Pre-IND Meeting with FDA on Comparable…
Press releases — page 4
AXIM Biotech Announces Successful Completion of Pre-IND Meeting with FDA on Comparable Product to Marinol; Green Light from FDA for IND Submission
December 12, 2017
Alternate Health's Investor Webcast And Presentation Now Available For On-Demand Viewing At VirtualInvestorConferences.com
December 11, 2017
Leading CBD Provider Reports 255% Revenue Growth -- CFN Media
November 27, 2017
Axim Biotechnologies Reports Third Quarter 2017 Results
November 22, 2017
Medical Marijuana, Inc. Reports Third Quarter 2017 Financial Results and Operational Highlights: Shows Record 255% Gross Profit Increase
November 21, 2017
Axim Biotechnologies Announces Phase IIa Trial Results Validating its Proprietary Cannabinoid Delivery Method for Treatment of Irritable Bowel Syndrome (IBS)
November 21, 2017
AXIM Targets Cannabinoid-based Ophthalmic Solutions -- SECFilings.com
October 25, 2017
New U.S. Patent Allowance Granted to AXIM® Biotechnologies, Inc. for Cannabinoid Ophthalmic Solutions for Glaucoma and Conjunctivitis Treatment
October 5, 2017
The Surprising Benefits of Chewing and Resulting Biotech Innovations -- SECFilings.com
October 4, 2017
How to Capitalize on the $1 Billion Hemp Industry -- CFN Media
September 11, 2017
AXIM Biotech to Present at Rodman & Renshaw 19th Annual Global Investment Conference in New York City
September 7, 2017
How Cannabis Could Solve the Opioid Crisis -- SECFilings.com
August 31, 2017
AXIM Biotechnologies Reports Second Quarter 2017 Results
August 22, 2017
Zynerba Failure Highlights the Need for Expertise, Broader Portfolios -- SECFilings.com
August 15, 2017
Medical Marijuana, Inc. Major Investment AXIM Biotech Enters Clinical Study Agreement with University of British Columbia to Begin Clinical Trial On CBD Chewing Gum For Treatment of Drug-Related Psychosis
August 3, 2017
AXIM Biotech Enters Clinical Study Agreement with University of British Columbia to Begin Clinical Trial On CBD Chewing Gum For Treatment of Drug-Related Psychosis
August 2, 2017
Dr. Stuart Titus, Chief Executive Officer of Medical Marijuana, Inc., Discusses Recent News and Events in a New Audio Interview at SmallCapVoice.com
August 2, 2017
Medical Marijuana, Inc Major Investment AXIM Biotech Enters Agreement With Israel-Based CRO To Begin Clinical POC Study For Treatment Of Restless Leg Syndrome
July 27, 2017
Top 4 Companies Reinventing Cannabinoid Delivery -- CFN Media
July 26, 2017
AXIM Biotech: Cannabinoid Potential Worth the Complexity -- SECFilings.com
July 24, 2017
AXIM Biotech Enters Services Agreement With Israel-Based CRO to Begin Clinical POC Study on CBD and Gabapentin Chewing Gum for Treatment of Restless Leg Syndrome
July 20, 2017
AXIM Biotech Holds Bi-Annual Board Meeting in New York City on July 8
July 12, 2017
Reuters Features Medical Marijuana, Inc.'s Major Investment Company AXIM Biotech In Article Citing Company's Development Of Marijuana-Based Painkiller To Combat Opioid Crisis
June 27, 2017
AXIM Biotechnologies (OTCQB: AXIM) Takes on Opioid Epidemic with New Patent -- SECFilings.com
June 27, 2017
Medical Marijuana, Inc. Major Investment AXIM Biotech Files Patent On Controlled Release Chewing Gum To Provide Opioid Addiction Treatment
June 26, 2017
AXIM Biotech Files Patent on Controlled Release Chewing Gum to Provide Opioid Addiction Treatment
June 23, 2017
AXIM® Biotechnologies Secures Funding to Advance Clinical Trials and Bioequivalency Study
June 19, 2017
AXIM Biotech to Present at 2017 Marcum Microcap Conference in New York City
June 14, 2017
Medical Marijuana Reports Strong Financial Results in 2016 -- CFN Media
June 6, 2017
AXIM Biotech to Present at 6th Annual SeeThruEquity Microcap Investor Conference in New York City
June 1, 2017
AXIM Biotech to Present Research Abstracts at the 6th Pharmaceutical Sciences World Congress
May 23, 2017
AXIM Biotech Soars After Analyst Issues $17 Price Target -- SECFilings.com
May 18, 2017
SeeThruEquity Initiates Coverage On Medical Marijuana, Inc. Investment Company AXIM Biotech (OTC: AXIM) With A Target Price Of $17.00
May 17, 2017
SeeThruEquity Initiates Coverage on AXIM® Biotechnologies (OTC: AXIM) With a Target Price of $17.0
May 16, 2017
SeeThruEquity Initiates Coverage on AXIM® Biotech (OTC: AXIM) With a Target Price of $17.0
May 16, 2017
AXIM Biotech Clinical Study to Develop Bioequivalent Product to Marinol Listed on Clinicaltrials.gov
May 15, 2017
AXIM® Biotech Expands Advisory Board With Oncology Specialist and Medicinal Cannabis Leading Expert – Dr. Donald Abrams
May 9, 2017
AXIM Biotech Advances Multiple Sclerosis Program -- SECFilings.com
May 4, 2017
Medical Marijuana, Inc. Major Investment AXIM Biotech Moves Forward With Development Of MedChew Rx Pharmaceutical Chewing Gum
May 3, 2017
AXIM Biotech Receives Schedule 1 Permit to Move Forward With Development of MedChew Rx Pharmaceutical Chewing Gum
May 2, 2017
Medical Marijuana, Inc. Reports Year End 2016 Financial Results and Operational Highlights - Product Sales by Quarter Increased 66% Q1-Q4
May 2, 2017
Top Three Best Performing Cannabis Stocks Over the Past Year -- SECFilings.com
April 27, 2017
AXIM Biotech to Present at ExcipientFest 2017 in Providence, Rhode Island
April 26, 2017
AXIM Biotech Advisory Board Member Presented at CannMed 2017 Personalized Cannabinoid Medicine Conference at Harvard
April 13, 2017